Cell therapy (CAR-T) · Kills target cells, directed at MUC16 (CA125) (MUC16) · developed by Precigen
PRGN-3005 is an autologous T-lymphocyte preparation genetically modified with the Sleeping Beauty transposon system to express an anti-MUC16 chimeric antigen receptor, a membrane-bound IL-15 and a safety switch. The CAR-T cells bind MUC16-expressing tumor cells to induce selective toxicity. It is studied in platinum-resistant, recurrent and refractory ovarian, fallopian tube and primary peritoneal carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03907527 | Phase 1 | Platinum-Resistant Fallopian Tube Carcinoma | Active not recruiting | PGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRefractory Fallopian Tube CarcinomaRefractory Ovarian CarcinomaRefractory Primary Peritoneal CarcinomaStage III Fallopian Tube Cancer AJCC V8Stage III Ovarian Cancer AJCC V8Stage III Primary Peritoneal Cancer AJCC V8Stage IIIA Fallopian Tube Cancer AJCC V8Stage IIIA Ovarian Cancer AJCC V8
See PGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PGEN catalysts and pipeline →